WallStreetZenWallStreetZen

NASDAQ: LUCY
Innovative Eyewear Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their LUCY stock forecasts and price targets.

Forecast return on equity

Is LUCY forecast to generate an efficient return?

Company
-31.9%
Industry
18.77%
Market
135.71%
LUCY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LUCY forecast to generate an efficient return on assets?

Company
-28.52%
Industry
13.96%
LUCY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LUCY earnings per share forecast

What is LUCY's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.48
Avg 2 year Forecast
-$0.46

LUCY revenue forecast

What is LUCY's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$7.3M+175.92%
Avg 2 year Forecast
$22.4M+743.08%
LUCY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LUCY revenue growth forecast

How is LUCY forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
175.92%
Industry
6.5%
Market
170.37%
LUCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LUCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LUCY vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
LUCY$1.03N/AN/A
CUPR$0.25N/AN/A
NXGL$0.58$2.00+244.23%Strong Buy
GCTK$0.80N/AN/A
BNGO$1.18$6.00+408.47%Buy
View Top Medical Stocks

Innovative Eyewear Stock Forecast FAQ

What is LUCY's earnings growth forecast for 2026-2027?

(NASDAQ: LUCY) Innovative Eyewear's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 297.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,428.39%.

Innovative Eyewear's earnings in 2026 is -$7,591,189.On average, 3 Wall Street analysts forecast LUCY's earnings for 2026 to be -$9,318,678, with the lowest LUCY earnings forecast at -$8,953,239, and the highest LUCY earnings forecast at -$9,592,756.

In 2027, LUCY is forecast to generate -$2,892,003 in earnings, with the lowest earnings forecast at -$2,778,592 and the highest earnings forecast at -$2,977,062.

If you're new to stock investing, here's how to buy Innovative Eyewear stock.

What is LUCY's revenue growth forecast for 2026-2027?

(NASDAQ: LUCY) Innovative Eyewear's forecast annual revenue growth rate of 175.92% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 6.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 170.37%.

Innovative Eyewear's revenue in 2026 is $2,661,669.On average, 3 Wall Street analysts forecast LUCY's revenue for 2026 to be $46,272,054, with the lowest LUCY revenue forecast at $44,457,464, and the highest LUCY revenue forecast at $47,632,997.

In 2027, LUCY is forecast to generate $141,386,833 in revenue, with the lowest revenue forecast at $135,842,251 and the highest revenue forecast at $145,545,269.

What is LUCY's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: LUCY) forecast ROA is -28.52%, which is lower than the forecast US Medical Instruments & Supplies industry average of 13.96%.

What is LUCY's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: LUCY) Innovative Eyewear's current Earnings Per Share (EPS) is -$1.90. On average, analysts forecast that LUCY's EPS will be -$1.48 for 2026, with the lowest EPS forecast at -$1.42, and the highest EPS forecast at -$1.52. In 2027, LUCY's EPS is forecast to hit -$0.46 (min: -$0.44, max: -$0.47).

What is LUCY's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: LUCY) forecast ROE is -31.9%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.